The Taiwan‐ADNI workflow toward integrating plasma p‐tau217 into prediction models for the risk of Alzheimer's disease and tau burden
The emergence of anti-amyloid therapy increases the need to accurately diagnose Alzheimer's disease (AD). The use of plasma biomarkers, especially phosphorylated tau 217 (p-tau217), can help in the diagnosis of AD. P-tau217 is a better predictor of amyloid positron emission tomography (PET) positivity than other core biomarkers. In amyloid PET-positive individuals, p-tau217 can predict tau burden. We propose a two-step workflow to identify AD cases suitable for treatment.
Authors
- Chin‐Chang Huang (ORCID: https://orcid.org/0000-0001-9894-9510)
- Ing‐Tsung Hsiao (ORCID: https://orcid.org/0000-0002-5255-7498)
- Kun‐Ju Lin (ORCID: https://orcid.org/0000-0003-1933-4564)
- Kuo‐Lun Huang (ORCID: https://orcid.org/0000-0001-8215-721X)
- Mi‐Chia Ma
- Chiung‐Chih Chang (ORCID: https://orcid.org/0000-0002-6721-2556)
- Hsin‐I Chang (ORCID: https://orcid.org/0009-0007-2390-6883)
- Chi‐Wei Huang (ORCID: https://orcid.org/0000-0002-2868-3961)
- Shu‐Hua Huang (ORCID: https://orcid.org/0000-0001-6542-5315)
- Chung‐Guei Huang
Institutions
- National Sun Yat-sen University (TW)
- Chang Gung University (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/alz.14297
- Citations
- 9
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 13.24
Funders
- Clinical Trial Center, China Medical University Hospital
- Chang Gung Memorial Hospital
- Chang Gung Medical Foundation
- National Science and Technology Council